Report Highlights

U.S. Dietary Supplements: Market Overview

The U.S. is the largest national dietary supplements market in the world, with retail sales estimated at USD 61.8 billion in 2024. It operates under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which treats supplements as foods rather than drugs. Products reach shelves without premarket efficacy approval, so speed to market is faster than in pharmaceuticals, while enforcement shifts to post-market action.

The market departs sharply from the global norm. Where European and Asian markets rely heavily on pharmacy channels and tighter botanical rules, U.S. sales spread across mass retail, e-commerce and direct selling. The Council for Responsible Nutrition reports that roughly three in four adults use a supplement. Thousands of brands compete, and the top ten companies hold well under half of category value.

Growth Drivers in U.S. Dietary Supplements

Demographic ageing is the first driver. The U.S. Census Bureau counts more than 61 million Americans aged 65 and over, a cohort that anchors demand for vitamin D, calcium, vitamin B12 and omega-3 products. Baby boomers moving into their 70s increase purchases of joint, cognitive and bone-health formats, where physician recommendation carries strong weight.

The second driver is federal nutrition policy. The Dietary Guidelines for Americans, 2020–2025, highlight widespread nutrient shortfalls, which supports multivitamin and vitamin D use. The third driver is channel expansion: Amazon Subscribe & Save and Walmart+ subscription programs have normalized recurring supplement purchases, lifting repeat rates across mass-market brands.

Market Restraints and Entry Barriers in the U.S.

Entry barriers are regulatory rather than capital-driven. Under DSHEA, new dietary ingredients require a premarket notification to the FDA at least 75 days before marketing. Manufacturers must also comply with Current Good Manufacturing Practice rules in 21 CFR Part 111, and the Federal Trade Commission requires substantiation for every health claim under Section 5 of the FTC Act.

Enforcement risk and ingredient cost form the other constraints. FDA warning letters for undeclared or unapproved ingredients, including tianeptine-containing and sibutramine-adulterated products, regularly remove brands from market. California's Proposition 65 adds labeling exposure, while concentrated Chinese supply of vitamin C and B vitamins creates price volatility that smaller brands absorb.

Market Opportunities in U.S. Supplements

Near-term entry is strongest in functional categories with clear clinical narratives. Magnesium, electrolyte and protein-blend supplements are growing faster than the category average, and U.S. protein supplement sales alone are estimated at roughly USD 10 billion. Creatine, long dominated by Optimum Nutrition and GNC, now sells well in gummy and women-targeted formats.

Subscription models and GLP-1 companion products offer a second route. Consumers on semaglutide and tirzepatide are buying protein, fiber and micronutrient products, an incremental pool estimated at USD 1.5 billion in annual sales by 2030. Entrants that reach Costco and Amazon can scale without the slotting fees and shelf-space commitments required by Walgreens and CVS.

Market at a Glance

Leading Market Participants

Regulatory and Policy Environment for U.S. Supplements

The Food and Drug Administration oversees supplements under DSHEA and the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006, which requires serious adverse event reports within 15 business days. The FDA's Center for Food Safety and Applied Nutrition handles labeling and new ingredient notifications, while the NIH Office of Dietary Supplements funds research and publishes consumer fact sheets.

The Federal Trade Commission regulates advertising through its health products compliance guidance, and state attorneys general enforce consumer protection law. The Current Good Manufacturing Practice rule (21 CFR Part 111) phased in between 2008 and 2010 by business size. No federal subsidy exists for manufacturers, so entrants compete on compliance cost, which USP verification can partly offset.

Long-Term Outlook for U.S. Dietary Supplements to 2032

By 2032, U.S. retail sales are forecast to reach USD 88.4 billion, implying a 4.6% CAGR from the 2025 base. Growth will skew toward personalized and clinically tested products, with third-party verified brands gaining share from unverified imports.

Channel mix will shift further toward e-commerce and subscriptions, while Walmart and Costco extend private label. Winners will combine ingredient traceability with claims compliance. Firms relying on unsubstantiated structure-function claims will face sustained FTC and FDA enforcement exposure.